FDA Grants First-Ever Modified Risk Orders for Philip Morris’ ZYN Nicotine Pouches
Event summary
- The FDA issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of Philip Morris International’s ZYN nicotine pouches, allowing the company to market them as lower-risk alternatives to cigarettes.
- The authorized claim states that using ZYN instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
- ZYN was the first nicotine pouch authorized for sale in the U.S. following a rigorous scientific review in January 2025.
- Over half of surveyed adults who switched to ZYN reported no cigarette consumption in the past 30 days, with 80.7% reducing their cigarette use.
The big picture
The FDA’s decision underscores a shift toward harm reduction in tobacco regulation, contrasting with global bans on nicotine products. Philip Morris’ ZYN approval strengthens its position as an industry leader in smoke-free alternatives, with 43% of its Q1 2026 revenue derived from such products. The move could pressure competitors to accelerate their own reduced-risk product pipelines.
What we're watching
- Regulatory Precedent
- Whether the FDA’s approval of ZYN sets a precedent for other nicotine pouch products, potentially accelerating market entry and competition.
- Consumer Adoption
- The pace at which smokers transition to ZYN and other smoke-free alternatives, impacting Philip Morris’ revenue mix and long-term strategy.
- Global Policy Contrast
- How the U.S. regulatory approach compares to international policies that favor bans over scientific evaluation, affecting Philip Morris’ global strategy.